|
|
Cytogenix Incorporated - Comparative Business Analysis Snapshot
Business Description
Cytogenix Incorporated. The Company's principal activities are developing and marketing proprietary technology for identifying and silencing disease causing genes. The technology of the Company prevents genetically diseased cells from manufacturing harmful proteins, thereby preventing disease. It owns patented intracellular expression system technology (CYGXes) to produce any desired sequence-specific, ssDNA molecules (ODN) in individual cells for the purpose of triplex, antisense, catalytic DNA, and aptamer applications. It seeks to market and license its technology to biotechnology companies owning DNA sequences in the Human Genome and to assist in their determination of the function and purpose of these sequences. The Company primarily operates in the United States.
Competitor Analysis
This analysis compares Cytogenix Incorporated with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
